Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate-Reference-Cited by-同舟云学术

Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

Published:2019-01-30 Issue:10 Volume:195 Page:872-881
ISSN:0179-7158
Container-title:Strahlentherapie und Onkologie
language:en
Short-container-title:Strahlenther Onkol

Author:

Yildirim Berna Akkus,Onal Cem^ORCID,Kose Fatih,Oymak Ezgi,Sedef Ali Murat,Besen Ali Ayberk,Aksoy Sercan,Guler Ozan Cem,Sumbul Ahmet Taner,Muallaoglu Sadık,Mertsoylu Huseyin,Ozyigit Gokhan

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Radiology Nuclear Medicine and imaging

Link

http://link.springer.com/article/10.1007/s00066-019-01429-6/fulltext.html

Reference35 articles.

1. Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics, 2017. CA Cancer J Clin 67(1):7–30. https://doi.org/10.3322/caac.21387

2. Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP (2015) Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol 194(6):1537–1547. https://doi.org/10.1016/j.juro.2015.06.106

3. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr., Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-301 Investigators (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995–2005. https://doi.org/10.1056/NEJMoa1014618

4. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, AFFIRM Investigators (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187–1197. https://doi.org/10.1056/NEJMoa1207506

5. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147–1154. https://doi.org/10.1016/S0140-6736(10)61389-X

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Local Treatment for Oligometastasis: A Comparability Based Meta-Analysis;Cancer Research and Treatment;2022-10-15

2. Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer;Current Molecular Pharmacology;2022-01

3. Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer;Frontiers in Oncology;2021-09-23

4. Radiotherapy in nodal oligorecurrent prostate cancer;Strahlentherapie und Onkologie;2021-04-29

5. Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer;Frontiers in Oncology;2021-04-19